Diabetes Prevention Program Outcomes Study (DPPOS)

Type 2 diabetes mellitus (T2DM) is a long-term metabolic disorder distinguished by high blood sugar, insulin resistance, and low insulin.  In our landmark study, the Diabetes Prevention Program (DPP) demonstrated that lifestyle changes or metformin could delay diabetes in a population at high risk of diabetes compared to placebo in the short term over 3 years and long term over 15 years.  The participants from the DPP continue their follow-up regardless of their diabetes diagnosis in the Diabetes Prevention Program Outcomes Study (DPPOS).   The goal of DPPOS is to study whether the benefits of postponing diabetes demonstrated in the DPP would translate into long-lasting impact.  The primary objectives of DPPOS are to determine the effect of early DPP interventions on 1) persistence of T2D development; 2) early microvascular disease, and 3) CVD risk factors 4)  Cancer and 5) Cardiovascular disease.




Marinella Temprosa, PhD


Sharon Edelstein, MsC
Costas Christophi, PhD
Mary Foulkes, PhD
John Lachin, DSc
Naji Younes, PhD
Qing Pan, PhD

Tsedenia Bezabeh, MS
Anna Bowers
Jamie Chang
Valerie Donohue, MBA
Adrienne Gottlieb, MS
Ashley Hogan Tjaden, MPH
Jinxi Liu, MS
Hermine Blagrove-Riley
Hanna Sherif, MS
Mark Tripputi, PhD

All DPP and DPPOS Publications can be found at the DPPOS website

Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Haffman HJ, Brenneman AT, Brown-Friday JO, Goldberg R, Venditti E, Nathan DM. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet, 2009;14(374):1677-1686.

Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. The Lancet Diabetes & Endocrinology, 2015;3(11):866-75.

Florez JC, Jablonski KA, Bayley N, Pollin TI, de Bakker PI, Shuldiner AR, Knowler WC, Nathan DM, Altshuler D, Diabetes Prevention Program Research Group. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. The New England Journal Of Medicine, 2006;355(3):241-250.

Diabetes Prevention Program Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care, 2002;25(12):2165-2171.

Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, Hoskin M, Kriska AM, Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, Venditti B, Wylie-Rosett J. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care, 2006;29(9):2102-7.

Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler SE, Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med, 2005;142(8):611-619.


Project Overview:

The DPPOS aims to assess the long-term effects of interventions used in the Diabetes Prevention Program (DPP) on the development of type 2 diabetes and its complications.

Major findings/impact of study:

The DPPOS demonstrated that the effects of the original interventions, intensive lifestyle and metformin persisted for at least 15 years, albeit with somewhat reduced efficacy (Lancet, 2009 and Lancet Diabetes & Endocrinology 2015). The lifestyle intervention and metformin groups reduced the rate of developing type 2 diabetes compared to placebo. CVD risk factors were shown to be reduced in the original lifestyle intervention group in the setting of fewer hypolipidemic and anti-hypertensive agents being used (Lancet 2009).